Author:
Lira-González Fidel Ángel,Jiménez-Ávila José María,Ruiz-Alonso Pedro Misael,García-Lamas Lizbeth,García-Hernández Diana,Guzmán-Silahua Sandra,Rubio-Jurado Benjamín,Nava-Zavala Arnulfo Hernán
Reference41 articles.
1. Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Blood. 1947;2(6):542-554. Blood. 2016; 127: 169.
2. Sukumar S, Lammle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021; 10: 536.
3. Joseph A, Joly BS, Picod A, Veyradier A, Coppo P. The specificities of thrombotic thrombocytopenic purpura at extreme ages: a narrative review. J Clin Med. 2023; 12: 3068.
4. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339: 1578-1584.
5. Du P, Cristarella T, Moride Y. A Systematic Review of the Current Epidemiology of Immune-Mediated and Congenital Thrombotic Thrombocytopenic Purpura caused by Severe ADAMTS13 Deficiencies [abstract]. [Accessed January 26, 2024] Available in: https://abstracts.isth.org/abstract/a-systematic-review-of-the-current-epidemiology-of-immune-mediated-and-congenital-thrombotic-thrombocytopenic-purpura-caused-by-severe-adamts13-deficiencies/